Sunday 20th May, 2012   |   Welcome, guest. Please, login or register  
Tuesday November  3, 05:20

Systemic lupus erythematosus treatment: Positive clinical results

GSK: positive clinical results for lupus treatment
GSK: positive clinical results for lupus treatment
 

The British pharmaceutical GlaxoSmithKline (GSK) and U.S. Human Genome Sciences (HGS) announced on Monday positive clinical results for a second study of treatment against systemic lupus erythematosus, a chronic inflammatory disease.

The study lasts for 76 weeks and involves 819 patients from 136 locations and 19 countries, which were administered different doses of Benlysta (belimumab) and the standard treatment against the disease, or a placebo and standard therapy.

A significant improvement was found in 43.2% of patients who received 10 mg/kg belimumab and the standard treatment against 33.8% who received placebo and standard therapy.

A first positive study was published in July.

According to the two groups, no new treatments against lupus has been launched on the market for over 50 years.

Systemic lupus erythematosus, which affects about 5 million people worldwide including 1.5 million in the United States, is expressed most frequently  in joint pain, skin lesions, facial and kidney damage, more or less severe, and can reach the nervous system and blood.

It is an autoimmune disease. The body attacks itself as if there were foreign elements. Current available treatments (corticosteroids, immunosuppressants) have palliative effects only.

90% of patients with lupus are women under 45 years.

Definition: A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.

 
Rate:
  •  
Please, login to rate the article.
 
 

Recommended articles:

 

Cancer: Fight against malignant melanoma

For the first time, two drugs have, each in turn, increase the survival of patients with metastatic forms
This is the beginning of a new era for melanomas and most formidable skin cancers. A drug targeted immunotherapy prolong survival in cases of metastasis.
 

On the trail of a vaccine against brain cancer

EGFRVIII marker is also found in other cancers (like breast or lung) but not in normal tissues
A therapeutic vaccine, tested in combination with conventional therapy in twenty patients, has extended survival by about 70%. These preliminary results have been obtained by the team of John Sampson at Duke University (United States).
 

Asthma: do follow your treatment!

Most patients with asthma do not follow their medication seriously
The difficulties in treating asthma are primarily due to poor monitoring of medication by patients, according to a study.
 

Most recent in the category Deseases:

 
 
 

Last comments

 

No comments. Be the first to comment the article!

Please, login to post comments.
 
 
 
 

Home | Social Health | AIDS | Cancer | Deseases | Diet | Human body | Most read | Top rated

RSS | Feedback | Headlines for your website | Terms of Service/Privacy policy

Copyright © 2012 Heal-all.org. All rights reserved.